問卷

TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Thoracic Medicine

Division of Thoracic Medicine

更新時間:2023-09-19

唐士恩
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

16Cases

2023-02-01 - 2024-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-02-01 - 2026-06-22

Phase III

Active
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
  • Condition/Disease

    Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)

  • Test Drug

    Amikacin liposome inhalation suspension (ALIS)

Participate Sites
12Sites

Not yet recruiting6Sites

Recruiting2Sites

Terminated4Sites

2023-06-01 - 2025-06-23

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2020-11-02 - 2024-04-30

Phase III

Completed
A phase 3, randomized, double-blind, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of Brensocatib administered once a day to subjects with non-cystic fibrosis bronchiectasis for 52 weeks – ASPEN test
  • Condition/Disease

    Non-cystic fibrotic bronchiectasis

  • Test Drug

    Brensocatib (INS1007)

Participate Sites
7Sites

Recruiting7Sites

2023-06-01 - 2025-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-01-15 - 2029-06-30

Phase III

Active
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    Pembrolizumab (MK-3475) / 商品名:KEYTRUDA/吉舒達

Participate Sites
7Sites

Recruiting4Sites

Terminated1Sites

2021-12-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-07-18 - 2021-08-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 2